Status:

COMPLETED

A Clinical Trial of Zutectra in Patients Who Recently Received a Liver Transplant

Lead Sponsor:

Biotest

Collaborating Sponsors:

AMS Advanced Medical Services GmbH

Conditions:

Hepatitis B

Eligibility:

All Genders

18-75 years

Phase:

PHASE3

Brief Summary

Patients who receive liver transplantation for hepatitis B virus (HBV) induced liver failure require longterm therapy to prevent HBV reinfection of the transplanted liver. The approved preventative tr...

Eligibility Criteria

Inclusion

  • Written informed consent obtained prior to orthotopic liver transplantation (OLT) - not more than 3 months before OLT
  • Historical evidence within the last 4 weeks that HBV-DNA is undetectable at time point of signature of Informed Consent
  • Male and female patients (age 18-75 years)
  • Patients with the diagnosis of liver failure with hepatitis B infection
  • Patients undergoing liver transplantation or re-transplantation
  • HBsAg negative on day 7 or on day 14 after OLT
  • HBV-DNA undetectable at OLT
  • Serum HBs antibody concentration on day 7 or on day 14 after OLT ≥ 400 IU/l
  • Stable patient in a condition which in the opinion of the investigator would permit safe participation in the study
  • Willingness to fill out patient diary

Exclusion

  • Re-transplantation due to viral recurrence
  • Positive HIV or HCV test at time of transplantation
  • HBV-DNA positive at OLT
  • Patients having received organs from HBsAg positive donors
  • Pregnancy or unreliable contraceptive measures or lactation period (females only)
  • Known intolerance to immunoglobulins or comparable substances (e.g. vaccination reaction)
  • Known intolerance to proteins of human origin
  • Participation in another interventional clinical trial within 90 days before entering the study or during the study and/or previous participation in this study (except screening failures)
  • Suspicion of drug and/or alcohol abuse
  • Inability or lacking motivation to participate in the study
  • Employee or direct relative of an employee of the CRO, the study site, or Biotest

Key Trial Info

Start Date :

December 1 2012

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2014

Estimated Enrollment :

49 Patients enrolled

Trial Details

Trial ID

NCT01856413

Start Date

December 1 2012

End Date

September 1 2014

Last Update

March 25 2015

Active Locations (16)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (16 locations)

1

Hopital de la Croix Rousse

Lyon, France, 69004

2

Hôpital Paul Brousse

Villejuif, France, 94804

3

Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari

Bari, Italy, 70124

4

S. Orsola Hospital

Bologna, Italy, 40138